BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37679770)

  • 1. CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (
    Grand-Guillaume J; Mansi R; Gaonkar RH; Zanger S; Fani M; Eugster PJ; Beck Popovic M; Grouzmann E; Abid K
    J Transl Med; 2023 Sep; 21(1):604. PubMed ID: 37679770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.
    Martiniova L; Perera SM; Brouwers FM; Alesci S; Abu-Asab M; Marvelle AF; Kiesewetter DO; Thomasson D; Morris JC; Kvetnansky R; Tischler AS; Reynolds JC; Fojo AT; Pacak K
    Endocr Relat Cancer; 2011 Feb; 18(1):143-57. PubMed ID: 21098082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
    More SS; Itsara M; Yang X; Geier EG; Tadano MK; Seo Y; Vanbrocklin HF; Weiss WA; Mueller S; Haas-Kogan DA; Dubois SG; Matthay KK; Giacomini KM
    Clin Cancer Res; 2011 Apr; 17(8):2339-49. PubMed ID: 21421857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for Increasing Uptake of Radiolabeled
    Pollard JH; Menda Y; Zamba KD; Madsen M; O'Dorisio MS; O'Dorisio T; Bushnell D
    Cancer Biother Radiopharm; 2021 Oct; 36(8):632-641. PubMed ID: 34252288
    [No Abstract]   [Full Text] [Related]  

  • 5. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.
    Zhang H; Huang R; Cheung NK; Guo H; Zanzonico PB; Thaler HT; Lewis JS; Blasberg RG
    Clin Cancer Res; 2014 Apr; 20(8):2182-91. PubMed ID: 24573553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
    Seo Y; Gustafson WC; Dannoon SF; Nekritz EA; Lee CL; Murphy ST; VanBrocklin HF; Hernandez-Pampaloni M; Haas-Kogan DA; Weiss WA; Matthay KK
    Mol Imaging Biol; 2012 Dec; 14(6):735-42. PubMed ID: 22382618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved selectivity of mIBG uptake into neuroblastoma cells in vitro and in vivo by inhibition of organic cation transporter 3 uptake using clinically approved corticosteroids.
    Bayer M; Schmitt J; Dittmann H; Handgretinger R; Bruchelt G; Sauter AW
    Nucl Med Biol; 2016 Sep; 43(9):543-551. PubMed ID: 27376201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
    Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
    Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Plasma Membrane Monoamine Transporter is Highly Expressed in Neuroblastoma and Functions as an mIBG Transporter.
    Vieira LS; Zhang Y; López Quiñones AJ; Hu T; Singh DK; Stevens J; Prasad B; Park JR; Wang J
    J Pharmacol Exp Ther; 2023 Dec; 387(3):239-248. PubMed ID: 37541765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells.
    Bayer M; Kuçi Z; Schömig E; Gründemann D; Dittmann H; Handgretinger R; Bruchelt G
    Nucl Med Biol; 2009 Apr; 36(3):287-94. PubMed ID: 19324274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
    Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells.
    Höpfner M; Sutter AP; Beck NI; Barthel B; Maaser K; Jockers-Scherübl MC; Zeitz M; Scherübl H
    Int J Cancer; 2002 Sep; 101(3):210-6. PubMed ID: 12209970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
    Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters.
    Kölby L; Bernhardt P; Levin-Jakobsen AM; Johanson V; Wängberg B; Ahlman H; Forssell-Aronsson E; Nilsson O
    Br J Cancer; 2003 Oct; 89(7):1383-8. PubMed ID: 14520475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake.
    Blom T; Meinsma R; Rutgers M; Buitenhuis C; Dekken-Van den Burg M; van Kuilenburg ABP; Tytgat GAM
    EJNMMI Res; 2020 Jul; 10(1):78. PubMed ID: 32642907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine.
    Höpfner M; Sutter AP; Huether A; Ahnert-Hilger G; Scherübl H
    BMC Cancer; 2004 May; 4():23. PubMed ID: 15154969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
    Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
    Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.
    Batra V; Makvandi M; Zuppa AF; Patel N; Elias J; Pryma DA; Maris JM
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27654664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.